Equities research analysts expect Axsome Therapeutics Inc (NASDAQ:AXSM) to announce earnings per share of ($0.33) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Axsome Therapeutics’ earnings. Axsome Therapeutics posted earnings of ($0.27) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 22.2%. The business is scheduled to report its next quarterly earnings results on Wednesday, November 14th.
On average, analysts expect that Axsome Therapeutics will report full-year earnings of ($1.15) per share for the current financial year, with EPS estimates ranging from ($1.18) to ($1.12). For the next year, analysts anticipate that the company will report earnings of ($0.70) per share, with EPS estimates ranging from ($1.15) to ($0.25). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Axsome Therapeutics.
Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Wednesday, August 8th. The company reported ($0.32) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.32).
A number of research analysts have recently commented on the company. HC Wainwright assumed coverage on Axsome Therapeutics in a research report on Thursday, June 7th. They set a “buy” rating and a $10.00 target price for the company. Zacks Investment Research upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, September 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $11.38.
AXSM stock opened at $3.30 on Monday. Axsome Therapeutics has a 1-year low of $2.05 and a 1-year high of $6.45. The company has a quick ratio of 2.26, a current ratio of 2.26 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $89.26 million, a price-to-earnings ratio of -2.66 and a beta of -0.15.
Hedge funds and other institutional investors have recently bought and sold shares of the company. A.R.T. Advisors LLC bought a new position in shares of Axsome Therapeutics during the 1st quarter valued at approximately $145,000. Sabby Management LLC bought a new position in shares of Axsome Therapeutics during the 1st quarter valued at approximately $199,000. Sio Capital Management LLC bought a new position in shares of Axsome Therapeutics during the 1st quarter valued at approximately $474,000. Finally, Alethea Capital Management LLC boosted its position in shares of Axsome Therapeutics by 132.5% during the 2nd quarter. Alethea Capital Management LLC now owns 270,823 shares of the company’s stock valued at $867,000 after acquiring an additional 154,323 shares during the last quarter. Hedge funds and other institutional investors own 15.63% of the company’s stock.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.
Featured Article: Beta
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.